/
KAPA
$0.36+$0.01 (+2.00%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$7.5M
21M shares
52-week range
$0.33 – $2.11
2% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
XASE
CS
Price (6 mo)
Loading chart…
Change$-2.24
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $98.0K | $160.0K | $160.0K | $160.0K | $0 |
| Gross profit | $0 | −$98.0K | −$160.0K | −$160.0K | −$160.0K | $0 |
| Gross margin | — | — | — | — | — | — |
| R&D | $20.0K | $183.0K | $87.0K | $82.0K | $414.0K | $2.1M |
| Operating income | −$1.0M | −$1.9M | −$571.0K | −$1.7M | −$2.3M | −$5.6M |
| EBITDA | −$1.0M | −$1.8M | −$411.0K | −$1.6M | −$1.6M | −$5.3M |
| Net income | −$1.1M | −$2.1M | −$1.1M | −$1.8M | −$2.6M | −$5.4M |
| Net margin | — | — | — | — | — | — |
| EPS (diluted) | -0.09 | -0.17 | -0.10 | -0.17 | -0.23 | -0.30 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-0.37 | $-0.37–$-0.37 | 1 |
| 2027 | $0 | $-0.67 | $-0.67–$-0.67 | 1 |
| 2028 | $0 | $-0.73 | $-0.73–$-0.73 | 1 |
| 2029 | $28M | $-0.46 | $-0.46–$-0.46 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.23
Price
$0.36
Implied downside
-34%
Peer comparison
Kairos Pharma, Ltd.
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
www.kairospharma.com- Employees
- 1
- IPO / List date
- Sep 16, 2024
- HQ
- LOS ANGELES, CA
Held by traders on TradeandTell
No one on the platform currently holds KAPA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in KAPA as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded KAPA yet.
